CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 39 enrolled
Drug / intervention
Etoricoxib, followed by placebo (matching tablet, without active ingredient) +1 moredrug
Likely dose
Etoricoxib, followed by placebo (matching tablet, without active ingredient) 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01619150
NCT01619150Phase 2Completed
CompareCT.gov

A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.

C4Pain·interventional·Posted Jun 14, 2012·Updated Jul 23, 2013

In Brief

A Phase 2 clinical trial evaluating Etoricoxib, followed by placebo (matching tablet, without active ingredient) and Placebo (matching tablet, without active ingredient), followed by etoricoxib for Osteoarthritis. Completed, enrolled 39 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate which pain mechanisms that can be affected by etoricoxib compared to placebo (inactive medication)in subjects with painful knee osteoarthritis af 4 weeks of treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesDenmark
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 14, 2012
Enrollment StartJul 1, 2012
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.0 years ago

Interventions

Etoricoxib, followed by placebo (matching tablet, without active ingredient)drug

Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.

Placebo (matching tablet, without active ingredient), followed by etoricoxibdrug

Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.